Primary sources below support the factual statements; templates, examples and proposed controls are original analytical recommendations. Dynamic pages should be rechecked before commitment.
Regulation, litigation and safety
- FDA — GLP-1 compounding policy and shortage-resolution updates.
- FDA — Drug Shortages Database.
- Fifth Circuit — Tirzepatide shortage opinion, August 27, 2026.
- Fifth Circuit — Semaglutide shortage opinion, revised September 1, 2026.
- FDA — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list.
- Federal Register public-inspection notice — Extension of the comment period to July 30, 2026.
- FDA — Prescription requirement under 503A, final guidance.
- FDA — Essentially copies under 503A, final guidance.
- FDA — Bulk drug substances under 503B.
- FDA — Outsourcing-facility registration questions and answers.
- FDA — Registered outsourcing facilities.
- FDA — Compounding inspections, recalls and other actions.
- FDA — Form 483 frequently asked questions.
- FDA — Concerns with unapproved GLP-1 drugs.
- FDA — Dosing errors associated with compounded injectable semaglutide.
- Arizona Board of Nursing — FDA multidose-vial safety letter.
- FDA — Wholesale-distributor and third-party-logistics licensure reporting.
- FDA — DSCSA exemptions.
State licensing, privacy and remuneration
- Texas State Board of Pharmacy — Licence verification.
- Texas State Board of Pharmacy — Nonresident pharmacy requirements.
- Texas State Board of Pharmacy — Class E application and processing guidance.
- California State Board of Pharmacy — Pharmacy lawbook.
- HHS — Business-associate guidance.
- HHS — Business-associate contract provisions.
- HHS OIG — Fraud-and-abuse laws.
Access, pricing and operating workflows
- LillyDirect — Healthcare-provider instructions.
- LillyDirect — Zepbound pricing and conditions.
- Eli Lilly — Zepbound prescribing information.
- NovoCare — Provider home-delivery instructions.
- NovoCare — Programme eligibility, prices and terms.
- CMS — Medicare GLP-1 Bridge.
- McKesson — Pharmaceutical-distribution capabilities and contact entry point.
- LumiMeds — Pharmacy Partnerships Specialist job description.
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- ca5.uscourts.gov · Source 3 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
- ca5.uscourts.gov · Source 4 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- fda.gov · Source 5 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- public-inspection.federalregister.gov · Source 6 ↗https://public-inspection.federalregister.gov/2026-12937.pdf
- fda.gov · Source 7 ↗https://www.fda.gov/media/97347/download
- fda.gov · Source 8 ↗https://www.fda.gov/media/98973/download
- fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- fda.gov · Source 11 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 12 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 13 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- fda.gov · Source 14 ↗https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 15 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- azbn.gov · Source 16 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
- fda.gov · Source 17 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers
- fda.gov · Source 18 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- pharmacy.texas.gov · Source 19 ↗https://www.pharmacy.texas.gov/DBSEARCH/default.asp
- pharmacy.texas.gov · Source 20 ↗https://www.pharmacy.texas.gov/licensees/nonresident-pharmacy-requirements.asp
- pharmacy.texas.gov · Source 21 ↗https://www.pharmacy.texas.gov/files_pdf/licensing/LIC-Class_E.pdf
- pharmacy.ca.gov · Source 22 ↗https://www.pharmacy.ca.gov/laws_regs/lawbook
- hhs.gov · Source 23 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- hhs.gov · Source 24 ↗https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample-business-associate-agreement-provisions/index.html
- oig.hhs.gov · Source 25 ↗https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
- lilly.com · Source 26 ↗https://www.lilly.com/lillydirect/hcp/
- lilly.com · Source 27 ↗https://www.lilly.com/lillydirect/zepbound
- uspl.lilly.com · Source 28 ↗https://uspl.lilly.com/zepbound/zepbound.html
- novocare.com · Source 29 ↗https://www.novocare.com/hcp/delivery.html
- novocare.com · Source 30 ↗https://www.novocare.com/eligibility/obesity-delivery.html
- cms.gov · Source 31 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- mckesson.com · Source 32 ↗https://www.mckesson.com/pharmaceutical-distribution/pharmaceutical-products/
- job-boards.greenhouse.io · Source 33 ↗https://job-boards.greenhouse.io/lumimeds/jobs/4356730009